A brief history of medicine: Huang Jiasi, former director of Shanghai Institute of Thoracic Diseases. 1963 was renamed Shanghai Institute of Cardiovascular Diseases, with Shen Kefei as its director. 1973, resume the establishment of the institute, with Shi Meixin as the director. Chen Haozhu, the current chairman, Shi Meixin, honorary chairman, and Ge Junbo, Zhao Qiang and Shu Xianhong, vice chairmen. The Institute currently has 107 employees, including full professors 10 and 30 associate professors. There are 6 doctoral supervisors and 7 master supervisors. The Institute has clinical and experimental departments such as cardiology (19 ward, 23 ward, 30 ward, CCU), cardiac surgery (3/kloc-0 ward, 32 ward, ICU), cardiac catheterization room, cardiac ultrasound diagnosis room, electrocardiogram room, key laboratory of viral heart disease of Ministry of Health, central laboratory, and cardiovascular epidemic statistics room. It has ten floors and a building area of 8442 square meters. It has relatively complete medical research facilities, including ultra-low temperature refrigerator, fluorescence microscope, floor-mounted high-speed centrifuge, desktop high-speed freezing centrifuge, quantitative PCR instrument, three-dimensional reconstruction instrument, ultrasonic ablation instrument, vertical electrophoresis instrument, high-voltage electrophoresis instrument, spectrophotometer and more than 30 advanced scientific research instruments and equipment. Since 1980, the institute has been designated as a cooperative center for cardiovascular research and training by the World Health Organization, and was approved as the Shanghai Cardiovascular Clinical Medical Center in 2002. Its Department of Cardiology is listed as a key discipline in national universities. Viral heart disease laboratory is the key laboratory of the Ministry of Health.
Main research fields: epidemiology and prevention of cardiovascular diseases, 1. Research on pathogenesis, diagnosis and treatment of coronary heart disease, including epidemiology, experimental atherosclerosis blood lipid biochemical research, X-ray contrast diagnosis and ultrasound diagnosis, interventional therapy of coronary heart disease, intravascular ultrasound diagnosis of coronary heart disease, surgical treatment of coronary heart disease and its complications, etc. 2. Study the pathogenesis, diagnosis and treatment of viral heart disease from the molecular level, including epidemiology, virology, immunological diagnosis and treatment of integrated traditional Chinese and western medicine; 3. Basic and clinical research on heart failure; 4. The study of cardiac ultrasound, including the application of esophageal ultrasound, intravascular ultrasound, multiplane transesophageal three-dimensional reconstruction ultrasound imaging and ultrasound ablation of coronary atherosclerosis; 5. Electrophysiological diagnosis and electrotherapy of arrhythmia, research and clinical application of artificial heart pacing technology; 6. Surgical treatment of valvular heart disease, treatment of various congenital heart diseases, research on new artificial heart valves and research on auxiliary circulation. Carry out coronary artery bypass grafting, heart transplantation (surgical treatment of end-stage heart disease) and artificial aortic valve transplantation.
Completed more than 50 projects at or above the municipal level, such as the National Seventh Five-Year Plan, the Eighth Five-Year Plan, the key projects of clinical disciplines of the Ministry of Health, and Shanghai Medical Leading College. At present, it is undertaking more than 20 national key basic research of 973 "863", Tenth Five-Year Plan, 2 1 1 project, Shanghai Cardiovascular Disease Clinical Medical Center, key projects of Shanghai Medical Development Fund and National Natural Science Foundation. The research funding reached120,000 yuan. In recent five years, he has won the scientific and technological progress award 14 at or above the municipal level, published 9 monographs and more than 450 papers, and won the patent 1 item.
Four postdoctoral fellows, 77 doctors, 77 masters, 4 postdoctoral fellows, 22 doctors and 32 masters have been trained.
Entrusted by the Ministry of Health, the Institute of Cardiovascular Diseases holds 26 national classes on cardiovascular diseases every year.
cardiovascular internal medicine
Zhongshan Hospital Affiliated to Fudan University
Cardiology, as a branch of internal medicine, was established in 1958. Its founder is Professor Tao Shouqi, a famous cardiovascular expert in China, and the first director of cardiology. 1989 was rated as a national key discipline. 1994 was rated as the leading discipline of Shanghai Health Bureau, and 1997 was listed as the key discipline in the "21/project" development plan. In 2002, it was designated as Shanghai Cardiovascular Clinical Medical Center and China Clinical Pharmacology Base.
The overall medical level of cardiology is leading in East China and among the best in China. Since 1950s, China has carried out left and right cardiac catheterization, electrophysiological examination of arrhythmia, external defibrillation cardioversion, coronary angiography, permanent pacemaker, external counterpulsation of coronary heart disease, catheter ablation of ventricular tachycardia, intravenous automatic pacing cardioversion defibrillator, intracoronary laser thrombolysis, intracoronary ultrasound and so on.
cardiac surgery
Department of Cardiology was established 1947, with Professor Huang Jiasi as the director. In the decades of development, it has achieved many domestic firsts. In China, it is the first to study the artificial static hanging screen cardiopulmonary machine, and carry out deep hypothermia open heart surgery, mitral insufficiency repair and atrial septal defect repair under cardiopulmonary bypass, such as VSD, ASD and France. 1978 Shanghai Valve Center was established to carry out research on domestic valves. The biological valve made of the same kind of dura mater, porcine aortic valve and bovine pericardium was successful, and the mitral valve, aortic valve and tricuspid valve were replaced by biological valves. The types of operation developed from single valve to double valve and triple valve replacement. And carry out aortic aneurysm, ascending aortic valve replacement, coronary artery bypass grafting, transposition of great vessels, localized hypertrophic cardiomyopathy (IHSS) and complex heart surgery. At present, various cardiac operations have been widely carried out, including congenital heart disease, valvular heart disease, coronary heart disease, large aneurysm, cardiac tumor, Marfan syndrome and end-stage cardiomyopathy. Among them, it is characterized by heart transplantation, surgical treatment of aortic dissection/aneurysm, minimally invasive cardiovascular surgery, valve repair and plastic surgery, and surgical treatment of complex coronary heart disease. There are more than 2,500 surgeries per year, and the success rate of surgery is as high as 98%. The level of treatment is in a leading position in China. Orthotopic heart transplantation for end-stage heart disease led by Professor Wang Chunsheng successfully won the second prize of China Medical Science and Technology Award and the second prize of Shanghai Science and Technology Award. In recent years, the applications of minimally invasive cardiovascular surgery include: minimally invasive mitral valve repair/replacement, minimally invasive aortic valve replacement, minimally invasive atrial septal defect repair, robot-assisted minimally invasive coronary artery bypass grafting, and minimally invasive maze surgery for atrial fibrillation. The scale of operation is leading in China and the curative effect is excellent.
Completed and undertaken a number of scientific research projects and won a number of scientific and technological achievement awards from the Ministry of Health and Shanghai. As the teaching and teaching of related chapters of cardiac surgery in Fudan University, as the national classroom teaching task and postgraduate teaching of cardiothoracic surgery. Invite foreign experts to give lectures and operations in our hospital, participate in the academic activities of foreign guests in other hospitals, and carry out academic exchanges and knowledge updates. Established: 1968
Brief medical history: The Institute of Liver Cancer of Fudan University was formerly the Cancer Group of Zhongshan Hospital of Shanghai First Medical College, and was established in 1968. 1969, the liver cancer group of Zhongshan Hospital was formally established with wards. 1978 was renamed as the liver cancer laboratory of Zhongshan Hospital, which was divided into two parts: ward and laboratory. Since then, it has continued to grow and develop. From 65438 to 0988, it was renamed as the Institute of Liver Cancer of Shanghai Medical University, which is affiliated to Shanghai Medical University. After the school merged in 2000, it was renamed the Institute of Liver Cancer of Shanghai Medical University. Hepatoma Research Institute is one of the two most important research centers for the prevention and treatment of liver cancer in China. It is a national key discipline (Oncology), Shanghai Hepatoma Clinical Medical Center, Shanghai Medical Leading Specialty (Liver Oncology), Shanghai Medical University (Oncology) "2 1 1 Project" and Shanghai Medical University "985 Project".
The clinical features are early diagnosis and treatment of liver cancer, and resection of unresectable liver cancer after volume reduction. In addition, surgical re-resection, freezing, microwave, ultrasound intervention, biological therapy and other special projects have been carried out one after another. Since 1995, the clinical comprehensive treatment research focusing on prevention and treatment of postoperative recurrence and metastasis of liver cancer has been carried out, and the comprehensive prevention and treatment scheme for postoperative recurrence of liver cancer has been explored to further prolong the survival period of patients with liver cancer and improve the prognosis. Accumulated nearly 4000 cases of liver cancer diagnosis and treatment experience. Early diagnosis and treatment of small liver cancer, resection after recurrence and resection after volume reduction of unresectable liver cancer, the 5-year survival rate is 60-70%. Up to now, 368 patients with liver cancer have survived for more than 5 years, 1 12 patients have survived for more than 10 years, and the longest survival time is 1 case in 38 years.
The laboratory consists of sterile animal model laboratory, cell biology laboratory, immunology laboratory, pathology laboratory, isotope laboratory, molecular biology laboratory and gene therapy laboratory. It has large equipment such as ultracentrifuge, capillary electrophoresis instrument, DNA synthesizer, polypeptide synthesizer, liquid scintillation analyzer and high performance liquid chromatograph. He has successively undertaken the research on major national scientific and technological issues from the Sixth Five-Year Plan to the Ninth Five-Year Plan, the American Chinese Medical Fund, and the Key Subject Fund of the Ministry of Health. He has won the first and third prizes of national scientific and technological progress, the first prize of Shanghai scientific and technological progress, several scientific and technological progress awards of the Ministry of Health, and the gold medal of American Cancer Institute. At present, he has undertaken the National Key Basic Research and Development Plan for Malignant Tumors (973) 1 subproject, two subprojects of the National Tenth Five-Year Plan for tackling key scientific and technological problems, two major projects of leading medical specialties in Shanghai, two key projects of the Shanghai Medical Development Fund, the National Natural Science Fund and the Ministry of Health Fund, and participated in the research of major projects such as the "863 High-tech Plan".
This hospital is the awarding point of doctoral and master's degrees of Fudan University. There is a postdoctoral mobile station (clinical medicine). At present, there are 7 doctoral supervisors and 5 master supervisors, and 3 postdocs, 42 doctors and 38 masters have been trained. Postdoctoral students 1 person, doctoral students 3 1 person, master students 15 people. Entrusted by the Ministry of Health, it undertakes the national continuing medical education project-the national progress study class on diagnosis and treatment of liver cancer every year.
Editor-in-chief of subclinical hepatocellular carcinoma and primary liver cancer in English, editor-in-chief of primary liver cancer (1 and version 2) and modern oncology (won the third prize of the National Science and Technology Progress Award). Invited to write ten internationally renowned monographs in Yu Ben. Take the lead in hosting four large-scale Shanghai international conferences on liver cancer and hepatitis and several national conferences on liver cancer. Professor Tang Zhaoyou once served as the representative of the Union for International Cancer Control in China (1990- 1998), 15 and 16, and attended hundreds of international conferences as a guest speaker. 1987 professor Tang zhaoyou, as one of the young scientists in China 14, was received by Deng Xiaoping and other party and state leaders.
Department status: liver cancer research, whole liver tumor surgery, internal medicine and laboratory composition. It has nearly 100 specialist beds and a well-equipped laboratory, covering an area of 900 square meters. The characteristic of the institute is the comprehensive treatment research based on surgical treatment, internal surgery, combination of traditional Chinese and western medicine, and combination of basic and clinical treatment. There are more than 40 health technicians, including professor 10 and associate professor (deputy chief physician) 12. Current Director: Professor Tang Zhaoyou, a famous expert in liver cancer surgery and academician of China Academy of Engineering.
Liver oncology department
1968 Cancer Group of Zhongshan Hospital was established. 65438-0969 formally established the liver tumor group of Zhongshan Hospital in the form of internal and external surgery, and set up a ward. 1978, with the approval of the Ministry of health, the liver cancer laboratory was formally established. 1988, the liver cancer laboratory was expanded into the Institute of Liver Cancer of Shanghai Medical University. Hepatooncology is a clinical department with primary liver cancer as the main direction and close combination of internal medicine and surgery. There are nearly 1000 cases of liver surgery in liver tumor surgery every year. The resection rate is 60-80%, the five-year survival rate is 40-50%, and the operative mortality rate is 1-3%, all of which are at the leading level in China. Early diagnosis and treatment of small liver cancer, resection after recurrence of liver cancer and reduction of unresectable liver cancer were first carried out in China, and the 5-year survival rate of small liver cancer after resection reached 60-70%. Especially the resection of huge liver tumor and the surgical diagnosis and treatment of hilar liver cancer. Liver transplantation has achieved good results in the treatment of end-stage cirrhosis, congenital liver metabolic disorder and cholestasis. In order to improve the detection rate of small hepatocellular carcinoma, a general survey and hepatic arteriography were carried out in the department of liver oncology in the early years. Followed by chemotherapy, immunization, traditional Chinese medicine and other comprehensive treatment. The internal medicine of liver tumor focuses on the non-surgical treatment of liver tumor and the prevention and treatment of postoperative recurrence and metastasis, and carries out radiation interventional therapy (hepatic arterial chemoembolization) and ultrasound-guided local therapy (internal local injection, portal vein chemotherapy and radiofrequency ablation). ), chemotherapy, biological therapy, etc.
general surgery
The founder of the discipline is Professor Shen Kefei, a famous surgeon. For more than half a century, through the efforts of several generations, the medical teaching and scientific research work of this discipline has been at the leading level in China, and famous surgeons at home and abroad such as Huang Jiasi, Cui Zhiyi, Feng Youxian, Meng, Wang Chengmeng and Wu have emerged. General surgery has done many major operations in China. Such as pancreaticoduodenectomy, regular hepatectomy, artificial blood vessel transplantation, inferior mesenteric vena cava anastomosis and so on. Indications: cholecystitis and cholelithiasis; Appendicitis; Benign thyroid tumor; Colorectal cancer; Gastric cancer; Pancreatitis; Pancreatic cancer; Cholangitis; Gallbladder cancer and cholangiocarcinoma; Portal hypertension; Thyroid cancer; Metastatic cancer. The main surgical operations are: cholecystectomy; Appendectomy; Thyroidectomy; Excision of breast lump; Exploration by laparotomy; High ligation and repair of inguinal pheasant hernia; Radical subtotal gastrectomy; Radical mastectomy; Right hemicolectomy; Repair of gastroduodenal perforation; Dixon operation; "Mile" surgery; Subtotal thyroidectomy; Left hemicolectomy; Total thyroidectomy; Modified radical mastectomy; Whipple operation; Partial hepatectomy; Total gastrectomy; Extended radical mastectomy; Total colectomy.
The main research directions are: surgical intensive care and surgical nutrition, comprehensive treatment of biliary and pancreatic diseases, gastrointestinal surgery research, gastrointestinal motility research, and endoscopic surgery. Yu Ben, the editor-in-chief and editor-in-chief of the textbook and major in 10, has undertaken more than 20 scientific research projects of the National Natural Science Foundation, ministries and commissions, and won the first prize of Shanghai Science and Technology Progress Award and other scientific and technological achievement awards. Established: 1936
Brief medical history: 65438-0936 The Department of Orthopaedics was established at the beginning of the establishment of Zhongshan Hospital, with Hongru Li as the director, which lasted for nearly 20 years. Clinically, it is mainly traumatic orthopedics. At the end of 1940s, the attempt of fracture open reduction and internal fixation was started. 1953, discography was first performed in China. Since 1962, we have carried out experimental research on small blood vessel surgery technology, studied a set of small blood vessels including microsurgical instruments, and summarized and compared the experience of different suture methods, different suture materials, small blood vessel transplantation and other basic technologies. 1963 upper arm replantation was successful. 65438-0966 In cooperation with Huashan Hospital, 5 cases of thumb reconstruction were successfully performed by one-stage transplantation of the second toe. 1970 completed the first metal total humeral replacement in Shanghai. In the same year, Shanghai type II artificial femoral head was successfully designed and popularized for the first time in Shanghai, and the original type I artificial femoral head was eliminated. 1974 took the lead in accepting the new concept of limb salvage and achieved the success of limb reconstruction. 1976 took the lead in emergency vascular free flap transplantation. Knee arthroscopy began in the same year, which contributed to the development of early arthroscopic surgery in Shanghai. 65438-0980 Rheumatoid arthritis patients underwent synovectomy or artificial joint replacement, and won the scientific and technological achievement award of the Ministry of Health. 1982, Academician Chen Zhongwei, known as "the father of microsurgery in the world", was transferred to Zhongshan Hospital as the director of orthopedics, and a central laboratory of microsurgery was established, holding national microsurgery classes and seminars every year. He designed iliac bone transplantation pedicled with deep circumflex iliac vessels to treat aseptic necrosis of femoral head in children and adults. 1988, the concept and technology of AO were first popularized in Shanghai. Indications: spine, joint, trauma, bone and soft tissue tumor, bone and joint tuberculosis, osteomyelitis, peripheral nerve injury, hand disease, congenital deformity of bone and joint, etc. Especially in trauma internal fixation technology, bone tumor, peripheral nerve injury, arthroscopy and discoscopy, lateral decompression of thoracolumbar segment, avascular necrosis of femoral head, chronic osteomyelitis and so on. In recent years, new technologies have been developed, such as "autologous bone marrow stem cell transplantation for femoral head necrosis" and "T-saw laminoplasty".
There are bone and joint tumor treatment center, arthroscopy center and tissue engineering center laboratory. In 2002, tissue engineering research was supported by two national natural science funds, and it undertook the "973" sub-project, several scientific research projects of the Ministry of Health and key projects of Shanghai Science and Technology Commission, and won several scientific and technological achievement awards of the Ministry of Health and Shanghai successively.
Department status: there are 64 approved beds and 34 doctors, including 5 professors and associate professors 10. There are 2 doctoral tutors and 5 master tutors. The annual operation volume 1500 is above, and the annual outpatient volume is above 50000.